Fig. 2.

Characterization of genomic alterations between primary and metastatic tissues in the index SFT case. a Genes mutated only in the metastatic tissue and incidences of each mutation from TCGA cancer subtype. b The mutated genes were confirmed by Sanger sequencing in the primary and metastatic tissues of the index case. c Molecular changes and protein expression of APAF1 and TP53 were validated by Sanger sequencing and immunohistochemical assay, respectively. dAPAF1 promoter DNA methylation on the SP1 binding motif was detected only in the metastatic tissues by bisulfite sequencing. e Reduction in APAF1 mRNA was quantified in primary and metastatic tissues of the index case using qRT-PCR (n = 3; bar represents the SE, Student’s t test. f APAF1 and TP53 protein expression were monitored through IHC of tissues obtained from patients with SFTs. Comparisons of TP53 immunopositivity and loss of APAF1 immunoreactivity in non-malignant and malignant solitary fibrous tumors are shown